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Abstract
Introduction Extracorporeal membrane oxygenation is a
supportive cardiopulmonary bypass technique for patients with
acute reversible cardiovascular or respiratory failure. Favourable
effects of haemofiltration during cardiopulmonary bypass
instigated the use of this technique in infants on extracorporeal
membrane oxygenation. The current study aimed at comparing
clinical outcomes of newborns on extracorporeal membrane
oxygenation with and without continuous haemofiltration.
Methods Demographic data of newborns treated with
haemofiltration during extracorporeal membrane oxygenation
were compared with those of patients treated without
haemofiltration in a retrospective 1:3 case-comparison study.
Primary outcome parameters were time on extracorporeal
membrane oxygenation, time until extubation after
decannulation, mortality and potential cost reduction.
Secondary outcome parameters were total and mean fluid
balance, urine output in mL/kg/day, dose of vasopressors, blood
products and fluid bolus infusions, serum creatinin, urea and
albumin levels.
Results Fifteen patients with haemofiltration (HF group) were
compared with 46 patients without haemofiltration (control
group). Time on extracorporeal membrane oxygenation was
significantly shorter in the HF group: 98 hours (interquartile
range (IQR) = 48 to 187 hours) versus 126 hours (IQR = 24 to
403 hours) in the control group (P  = 0.02). Time from
decannulation until extubation was shorter as well: 2.5 days
(IQR = 0 to 6.4 days) versus 4.8 days (IQR = 0 to 121.5 days;
P  = 0.04). The calculated cost reduction was €5000 per
extracorporeal membrane oxygenation run. There were no
significant differences in mortality. Patients in the HF group
needed fewer blood transfusions: 0.9 mL/kg/day (IQR = 0.2 to
2.7 mL/kg/day) versus 1.8 mL/kg/day (IQR = 0.8 to 2.9 mL/kg/
day) in the control group (P< 0.001). Consequently the number
of blood units used was significantly lower in the HF group (P<
0.001). There was no significant difference in inotropic support
or other fluid resuscitation.
Conclusions Adding continuous haemofiltration to the
extracorporeal membrane oxygenation circuit in newborns
improves outcome by significantly reducing time on
extracorporeal membrane oxygenation and on mechanical
ventilation, because of better fluid management and a possible
reduction of capillary leakage syndrome. Fewer blood
transfusions are needed. All in all, overall costs per
extracorporeal membrane oxygenation run will be lower.
Introduction
Extracorporeal membrane oxygenation (ECMO) is a support-
ive cardiopulmonary bypass (CPB) technique for patients with
acute reversible cardiovascular or respiratory failure. Many
ECMO candidates have an increased inflammatory response
with capillary leakage before the start of ECMO because of
asphyxia, hypoxia and shock. ECMO treatment in itself will trig-
ger or aggravate a systemic inflammatory response (SIRS),
resulting in a so-called capillary leakage syndrome [1]. High
levels of circulating endotoxins, exotoxins, interleukins and leu-
AaDO2: alveolar-arterial oxygen tension gradient; CDH: congenital diaphragmatic hernia; CPB: cardiopulmonary bypass; CVVH: continuous veno-
venous haemofiltration; ECMO: extracorporeal membrane oxygenation; ICU: intensive care unit; IQR: interquartile range; OI: Oxygenation Index; 
PELOD: pediatric logistic organ dysfunction; PRISM: Pediatric Risk of Mortality Score; SIRS: systemic inflammatory response syndrome.Critical Care    Vol 13 No 2    Blijdorp et al.
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kotrienes influence the basal membranes [2]. Moreover the
ECMO system activates leucocytes, thrombocytes and the
complement system [3,4]. This leads not only to water and
small molecule leakage through the capillary membrane, but
also to leakage of relatively large molecules, including albumin.
Permeation of circulating albumin from the blood compartment
into the extracellular space often results in generalised
oedema. The blood pressure will fall due to extravasation of
water and proteins, necessitating administration of oncotic
agents and/or vasopressor drugs. Low blood pressure and tis-
sue oedema will potentially cause deficient tissue perfusion
and oxygenation leading to multi-organ failure, of which lung
and kidney failure are most prominent.
As early as 20 years ago Zobel and colleagues described that
haemofiltration rapidly corrected hypervolaemia and pulmo-
nary oedema in nine critically ill children with multi-organ failure
[5]. In vitro and in vivo studies meanwhile have shown that
haemofiltration counteracts SIRS by decreasing inflammatory
mediators [6-8].
Later studies focused on haemofiltration as a method of pre-
venting multi-organ failure due to capillary leakage syndrome
in children during cardiac surgery on CPB [9]. Journois and
colleagues reported that haemofiltration resulted in the
removal of water and inflammatory proteins from the blood,
and consequently in less pulmonary oedema and improved
pulmonary function. Time on mechanical ventilation could
therefore be shortened and the postoperative alveolo-arterial
oxygen gradient improved [10,11]. Haemofiltration is also
associated with faster recovery of left ventricular function of
the heart, better diastolic compliance, better contractility and
less myocardial oedema as recorded by trans-oesophageal
echocardiography during CPB [12,13].
Kelly and colleagues reported that pulmonary oedema
increases time on ECMO [14]. The potentially favourable
effects of haemofiltration during CPB instigated the use of
haemofiltration in infants on ECMO in the Erasmus MC –
Sophia Children's Hospital since August 2004. It was
intended to prevent and diminish the capillary leakage syn-
drome, and thus to shorten time on ECMO, time on ventilatory
support, to lower numbers of blood transfusions, and conse-
quently to reduce overall mortality and costs in this group.
Therefore, since October 2004 in all patients receiving ECMO
a haemofilter was incorporated in the ECMO system inde-
pendent of kidney function. Initially the haemofilter was incor-
porated after cannulation due to logistic procedures. The
current case-comparison study aimed to evaluate the potential
benefit of haemofiltration in ECMO patients by comparing clin-
ical parameters in patients on ECMO with and without contin-
uous haemofiltration.
Materials and methods
Setting
The intensive care unit (ICU) of the Erasmus MC-Sophia Chil-
dren's Hospital, Rotterdam, the Netherlands, is a large tertiary
facility. It is one of two designated ECMO centres in the Neth-
erlands with 30 to 40 ECMO runs annually, including new-
borns and children up to 18 years of age. The referral area for
ECMO has eight million inhabitants with about 90,000 new-
borns annually.
Study design
This was a retrospective case-comparison study. Demo-
graphic data of all newborns (less than 28 days post partum)
on ECMO treated with haemofiltration (HF group) between
October 2004 and October 2006 were compared with new-
borns treated without haemofiltration (control group) in the
previous two years (October 2002 to October 2004) in a 1:3
case-comparison study. Cases and controls were matched for
age, weight, diagnosis and ECMO-mode. Inclusion criteria
were: in need of ECMO treatment, younger than 28 days and,
in the HF group, with haemofiltration. To evaluate the effects
of continuous veno-venous haemofiltration (CVVH) during
ECMO versus the control group, only those patients receiving
CVVH within three hours after starting ECMO were included.
We excluded patients treated with furosemide in the HF group
to eliminate possible confounding effects of additional diuretic
treatment on fluid management.
Controls consisted of a series of consecutive patients taken
from the previous two years who were not treated with haemo-
filtration. Controls were matched for age, weight, diagnosis
and ECMO-mode.
ECMO, haemofiltration and fluid management
The ECMO circuit was primed with 180 mL of a mixture of
packed red blood cells, albumin, 100 mL balanced electrolyte
solution saline-adenine-glucose-mannitol and 500 units
heparin. The ECMO flow at the start was set between 120 and
150 mL/kg/minute. Post-pump pressure was between 200
and 400 mmHg. The filter (Multiflow 60, Hospal, Lyon, France)
was placed parallel to the ECMO circuit, distal to the ECMO
roller pump. Pressure was measured proximal and distal to the
filter. The pressure difference was kept constant at 40 mmHg.
In the filtration group, the predilution flow rate of the filtration
fluid (HF-BIC32, Dirinco, Rosmalen, The Netherlands) was as
the default of 50 mL/kg/hour. Transfusions with erythrocytes
and platelets were administered isovolaemically by ultrafiltrat-
ing as much fluid from the patient as the administered blood
product. Ultrafiltration was targeted to achieve a normal or
negative fluid balance depending on the clinical condition of
the patient while maintaining normal haemodynamic parame-
ters. During SIRS and the resulting capillary leakage syndrome
this could not always be achieved. In the control group,
patients were treated with either continuous or intermittentAvailable online http://ccforum.com/content/13/2/R48
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furosemide infusions to achieve the above mentioned targets
as reported earlier by our group [15]. Transfusion of blood
products in this group were performed by isovolaemic
exchange with whole blood drawn from the ECMO system in
an equal amount to the transfused volume thereby maintaining
normal haemodynamic parameters. With some exceptions the
primary ECMO mode was veno-arterial.
Data collection and analysis
The following data were retrieved from our Patient Data Man-
agement System: physiological parameters, medication, infu-
sions, urinary output, CVVH, ECMO and ventilator settings,
fluid balance, laboratory tests and interventions. These data
had been collected every hour. Primary outcome measure-
ments were: time on ECMO in hours, time between decannu-
lation and extubation in days and overall mortality. Secondary
outcome parameters were: total and mean fluid balance, urine
output in mL/kg/day, total doses of vasopressors, blood prod-
ucts and fluid bolus infusions, serum creatinine, urea and albu-
min levels, and overall costs. Fluid balance was assessed as
mean net fluid balance per ECMO day, by measuring total fluid
input and output and dividing the difference by the time on
ECMO. The difference between predilution and filtration flow
rate was included.
The amount of inotropic support was calculated, as reported
previously, by the so-called vasopressor score: (dopamine
dose (μg/kg/minute) × 1) + (dobutamin dose (μg/kg/minute)
× 1) + (noradrenaline (μg/kg/minute) × 100) + (adrenaline
(μg/kg/minute) × 100) [16,17].
Statistics
All data are presented as median (interquartile range (IQR))
unless indicated otherwise. Differences between the groups
were tested for their statistical significance by Mann-Whitney
U non-parametric test for unpaired data, the Pearson's chi
squared test and the Fisher's exact test, according to the char-
acter of the variable. A P < 0.05 was considered significant.
Informed consent
Due to the design of the study consisting of a retrospective
case-record evaluation, Institutional Review Board approval
and the need for informed consent was waived according to
Dutch law.
Results
Patient profiles
Fifteen patients with haemofiltration (HF group) were com-
pared with 46 patients without haemofiltration (control group).
Patient characteristics are shown in Table 1. Median postpar-
tum age on admission was 2.2 days (IQR = 0.9 to 6.7 days) in
the HF group and 1.7 days (IQR = 0.5 to 18 days) in the con-
trol group. Median weight was 3.5 kg (IQR = 2.5 to 5 kg) in
the HF group and 3.3 kg (IQR = 1.9 to 5 kg) in the control
group.
Pediatric Risk of Mortality Scores (PRISM) III were calculated
retrospectively at the time of admission to the ICU. Most
patients were cannulated within 24 hours of admission. Pedi-
atric Logistic Organ Dysfunction (PELOD), Oxygenation Index
(OI) and Alveolar-arterial Oxygen Gradient (AaDO2) scores
were taken within six hours of cannulation. Although there are
more patients with congenital diaphragmatic hernia (CDH) in
the control group there are no significant differences in
PRISM, PELOD, OI and AaDO2 scores reflecting a similar
severity of illness before ECMO. CDH and meconium aspira-
tion syndrome were the most frequent indications for ECMO
therapy. Other diagnoses were respiratory distress syndrome,
viral or bacterial pneumonia, congenital cystic adenomatoid
malformation of the lung, persistent pulmonary hypertension,
post-cardiac surgery and sepsis.
In both groups, two children with isolated pulmonary disease
were treated with veno-venous ECMO. All other patients, 13
(87%) in the HF group and 44 (96%) in the control group,
were treated with veno-arterial ECMO. Three patients in the
HF group and four patients in the control group underwent
surgery during ECMO, that is, closure of a diaphragmatic
defect (n = 5), thoracotomy due to congenital cystic adenom-
atoid malformation of the lung (n = 1) or correction of a trans-
position of the great vessels (n = 1) for which post-cardiac
surgery ECMO was needed. Furosemide was administered to
40 children in the control group.
Outcome
Patient outcomes are listed in Table 2. Time on ECMO was
significantly shorter in the HF group: 98 hours (IQR = 48 to
187 hours) versus 126 hours (IQR = 24 to 403 hours) in the
control group (P = 0.02). Time from decannulation until extu-
bation was shorter as well, though not significantly: 2.5 days
(IQR = 0 to 6.4 days) versus 4.8 days (IQR = 0 to 121.5 days;
P = 0.04). Mortality rate was similar in both groups, 3 of 15 in
the HF group and 7 of 46 in the control group (P = 0.61). Fluid
balance per day on ECMO was significantly lower in the HF
group compared with the control group (P < 0.001).
Patients in the HF group needed fewer blood transfusions
than controls 0.9 mL/kg/day (IQR = 0.2 to 2.7 mL/kg/day) ver-
sus 1.8 mL/kg/day (IQR = 0.8 to 2.9 mL/kg/day; P < 0.001).
Consequently the number of used blood units was signifi-
cantly lower in the HF group (P < 0.001). No statistically sig-
nificant difference was observed between the two groups with
respect to volume and number of units of platelet and colloid
transfusions. Used colloid solutions included fresh frozen
plasma, pasteurised plasma solution and human albumin.
Maximal creatinine values were above normal range in both
groups, and tended to be lower in the HF group (P = 0.17).
Maximal urea level was significantly lower in the HF group (P
= 0.01). No significant difference was noted between the twoCritical Care    Vol 13 No 2    Blijdorp et al.
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 groups with respect to the lowest albumin value. Doses of
vasopressor did not differ significantly between the groups.
Costs
Although the need for additional support was higher in the ini-
tial phase of CVVH on ECMO personnel costs did not differ
between both groups. ECMO nurses were continuously avail-
able for the priming of the system and integrated the haemofil-
ter in the ECMO circuit. They took care of both the ECMO
circuit (with or without haemofilter) and the patient. A median
patient in the control group needed 28 hours more on ECMO
and 55 hours more on mechanical ventilation. The total costs
Table 1
Patient profiles
Control group
(n = 46)
HF group
(n = 15)
Pearson's chi squares test
n (%) n (%) P value
Sex Female 21 (46) 5 (33)
Male 25 (54) 10 (67) 0.44
Mann-Whitney U test
Scores PRISM III 37 (14 to 90) 35 (17 to 51) 0.29
PELOD 628(492 to 694) 633 (551 to 651) 0.93
OI 20 (1 to 30) 20 (10 to 20) 0.82
AaDO2 25 (14 to 39) 20 (14 to 40) 0.18
Pearson's chi squared test
Start ECMO Oct 2002 to Aug 2004 38 (83) 0(0)
Aug 2004 to July 2006 8 (17) 15 (100) -
Diagnosis CDH 16 (35) 3 (20)
MAS* 16 (35) 5 (33)
Respiratory diseases 7 (15) 2(13)
Sepsis 4 (9) 2 (14)
Idiopathic PPHN 2 (4) 2 (13)
Post-cardiac surgery 1 (2) 1 (7) 0.73
Surgery No surgery 42(91) 12 (80)
CDH closure 3 (7) 2 (13)
Great vessel surgery 1 (2) 1 (7) 0.24
ECMO mode Veno-arterial 44 (96) 13 (87)
Veno-venous 2 (4) 2 (13) 0.22
median (min to max) median (min to max)
Body weight (kg) 3.3 (1.9 to 5) 3.5 (2.5 to 5) 0.31
Age (days) 1.7 (0.5 to 18) 2.2 (0.9 to 6.7) 0.28
Values are presented as mean (interquartile range). * One patient died on ECMO.
AaDO2 = alveolar-arterial oxygen tension gradient; CDH = congenital diaphragmatic hernia; ECMO = extracorporeal membrane oxygenation; HF 
= haemofiltration; MAS = meconium aspiration syndrome; OI = Oxygenation Index; PELOD = pediatric logistic organ dysfunction; PPHN = 
persistent pulmonary hypertension of the neonate; PRISM = Pediatric Risk of Mortality Score.Available online http://ccforum.com/content/13/2/R48
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per day on ECMO, including costs for personnel, materials
and overheads, were calculated at €4328.
The mean total costs per day for treatment on an ICU ward
with mechanical ventilation in our institution amounted to
€1480. A median of an extra 5.4 units of blood were needed
per patient in the control group, representing €964. In the HF
group extra costs were generated by 1 or 2 filters (€90 each)
and a median of one 5 L bag of substitution fluid (€15).
The profit gained by adding haemofiltration to the ECMO cir-
cuit thus amounted to more than €5000.
Discussion
In 2008 Hoover and colleagues showed that the use of CVVH
in paediatric patients on ECMO is associated with improved
fluid balance and caloric intake and less diuretics than in case-
matched ECMO controls [18]. We report the first study in
newborns that shows that haemofiltration during ECMO
improves clinical outcome. This is expressed by a shorter dura-
tion of ECMO treatment, and of mechanical ventilation after
ECMO. Moreover, the use of haemofiltration resulted in fewer
blood transfusions in this group.
The calculated cost reduction for each haemofiltrated patient
was more than €5000. Although adding haemofiltration to an
ECMO circuit may result in the need for additional support, in
our centre our ECMO staff are trained to manage the CVVH
treatment negating the need for additionally trained nursing
support. Adding a treatment to an already complex patient may
result in treatment errors. This is always an issue in an ICU set-
ting and difficult to express in terms of cost. This said, we did
not have any complications in administering CVVH during
ECMO in the study.
Table 2
Patient outcome
Control group HF group Mann-Whitney U-test
Median (min to max) Median (min to max) P value
Time on ECMO (hours) 126 (24 to 403) 98 (48 to 187) 0.02
Time until extubation after decannulation (days) 4.8 (0 to 121.5) 2.5 (0 to 6.4) 0.04
Fluid balance (mL/kg/day) 40 (-53 to 214) -29 (-75 to 60) < 0.001
Urine (mL/kg/day) 121 (28 to 292) 54 (11 to 94) 0.38
Filtration flow rate in (L/kg/day) - 1.2 (0.6 to 1.4) -
Filtration flow rate out (L/kg/day) - 1.3 (0.6 to 1.7) -
Blood loss (mL/kg/day) 57 (8 to 135) 12 (6 to 30) < 0.001
Erythrocyte transfusion (mL/kg/day) 39 (0 to 73) 16 (0 to 35) < 0.001
Platelet transfusion (mL/kg/day) 37 (0 to 65) 29 (11 to 63) 0.11
Colloids (mL/kg/day) 6 (0 to 37) 4 (0 to 30) 0.25
Pasteurised plasma (mL/kg/day) 18 (0 to 98) 20 (2 to 69) 0.79
Units erythrocytes (units/day) 1.8 (0.8 to 2.9) 0.9 (0.2 to 2.7) < 0.001
Units thrombocytes (units/day) 0.9 (0.2 to 1.9) 0.7 (0.2 to 2) 0.3
Vasopressor score 7 (0 to 56) 5 (0 to 41) 0.83
Furosemide (mg/kg/day) 1.2 (0 to 2.6) - -
Bumetanide (mg/kg/day) 0 (0 to 0.27) - -
Maximum serum creatinine (μmol/l) 58 (14 to 91) 49 (28 to 105) 0.17
Maximum serum urea (mmol/l) 6 (1 to 42) 4 (2 to 13) 0.01
Minimum serum albumin 21 (2 to 30) 23 (13 to 28) 0.15
Mortality rate 7 (16)* 3 (21)*,** 0.61
Day of death after decannulation 3.4 (0 to 11.4) 1.5 (-0.5 to 6.4) 0.56
Values are presented as mean (interquartile range). * n (%), ** One patient died on ECMO.
ECMO = extracorporeal membrane oxygenation; HF = haemofiltration.Critical Care    Vol 13 No 2    Blijdorp et al.
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Capillary leakage syndrome is a frequent complication of CPB
and ECMO leading to generalised oedema, hypotension and
ultimately multi-organ failure. Several studies have reported
that the use of haemofiltration during and after CPB resulted
in less oedema and shorter post-operative ventilation [9-13].
Before starting ECMO, many ECMO candidates already have
an increased inflammatory response with capillary leakage
because of asphyxia, hypoxia and shock. In an effort to main-
tain a normal blood pressure, patients are treated with ino-
tropic support, but also unfortunately with ample fluid
supplementation. This therapy may result in an increase of
generalised oedema and subsequently pulmonary oedema.
ECMO treatment aggravates this inflammatory syndrome [1].
The higher need for blood transfusions in the control group is
most likely to be because of the possibility of isovolaemic
transfusion of blood and platelet transfusions via the haemofil-
ter in the HF group. This may in itself have a beneficial effect
on multi-organ failure. Bjerke and colleagues reported that
restricting blood transfusions in newborns on ECMO
decreased the running time of ECMO by 15% [19]. Tran and
colleagues studied factors associated with multi-organ failure
in patients with critical trauma. One such factor was the
number of blood transfusions received [20]. This relation may
be due to a nonspecific host response to transfusions, result-
ing in progressive multi-organ failure. Multi-organ failure score
is one of the major predictors of death on the ICU, so blood
transfusions contribute to worse clinical outcome. Modern
strategies to deplete red cell transfusions of leucocytes may,
however, decrease this risk, as recently indicated in critically ill
children by Lacroix and colleagues [21]. Nevertheless, restric-
tive blood transfusion strategy is recommended in children
whose condition is stable.
We did not demonstrate a favourable effect of haemofiltration
on multi-organ failure or capillary leakage, expressed as better
renal function, lower vasopressor score or less need for fluid
resuscitation. Creatinine levels were slightly elevated in both
groups [22], and tended to be lower in the haemofiltrated
group. The slightly lower level of serum creatinine and urea in
the filtrated group can, at least partially, be explained by the
convective clearing effect of haemofiltration. There was no sta-
tistical difference in other volume supplementations or ino-
tropic support. This study was not designed to evaluate the
effect of haemofiltration on SIRS. Due to the retrospective
nature of our study, levels of inflammatory mediators were
obtained from plasma, urine or filtrate were not available.
We did not find a statistically significant change in mortality
rate, but patient numbers in this study are too small to draw
conclusions on this aspect of the results. The total mortality
rate of 10 in a population of 61 patients (16%) is fairly low, in
comparison to both the mortality rate of 53 in a population of
188 patients (28%) in the previous 10 years of ECMO treat-
ment and the overall mortality rate of 24% in the Extracorpor-
eal Life Support Organization registry in newborns treated
with ECMO for respiratory failure. Addition of haemofiltration
increased fluid extraction during ECMO in our study,
expressed by a better overall fluid balance, in contrast to treat-
ment with diuretics.
Limitations of our study
In this case-comparison study patients were matched for most
confounding factors. Due to the relatively small sample size it
was not possible to perfectly match cases and controls, result-
ing in a higher percentage of patients with CDH in the control
group. We acknowledge that patients with CDH have a higher
overall mortality and morbidity, especially compared with
patients with meconium aspiration syndrome. This also applies
to patients with idiopathic pulmonary hypertension, constitut-
ing 13% of the cases. However, no significant differences in
baseline characteristics (Table 1) between the groups exists.
Both severity of illness expressed by PELOD and PRISM III
scores and severity of respiratory failure expressed by OI and
AaDO2 did not differ significantly.
Secondly the groups had been treated during different time
periods; however, patients in the HF group were treated two
years later than patients in the control group. As ECMO
haemofiltration was not introduced until August 2004, the HF
group in this single-centre, retrospective study consists of only
15 patients. No significant changes in indications for treatment
on ECMO took place over the years and patients were treated
by the same team without major infrastructural changes in our
ECMO setting.
Furthermore, no data were collected to detect a decrease in
inflammatory mediators. Therefore, it is not possible to evalu-
ate the potential favourable effects of haemofiltration on SIRS,
that is, through a mechanism that lowers the inflammatory
mediator response. An ongoing randomised controlled trial in
our institution is expected to yield more information to optimise
the value of haemofiltration during ECMO.
Conclusions
Adding continuous haemofiltration to the ECMO circuit in
newborns improves short-term outcome by significantly reduc-
ing time on ECMO and on mechanical ventilation, and by a
possible reduction of SIRS and capillary leakage syndrome.
Furthermore, significantly fewer blood transfusions are
needed. Haemofiltration during ECMO decreases costs per
ECMO run by €5000. Given the fact that 30 patients per year
receive ECMO treatment in our institution, a €150,000 cost
reduction per year could be accomplished.
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Key messages
￿  CVVH during ECMO reduces time on ECMO and time 
to extubation post-ECMO.
￿  CVVH during ECMO decreased the need for blood 
transfusions.
￿  CVVH during ECMO resulted in a €5000 cost reduc-
tion for each ECMO run.